glp 1 and restless leg syndrome Potential Use of GLP-1 GIP/GLP-1 Receptor Agonists for Respiratory Disorders: Where Are We at? glp 1 and restless leg

Tirzepatide: SURMOUNT-1 (72 Weeks) The SURMOUNT-1 trial enrolled 2,539 adults with obesity (BMI 30) or overweight with comorbidities

Remote Pharmacy Releases 2025 Availability Update on GLP-1 Weight Loss Solutions and Consumer Interest in Semaglutide & Tirzepatide In this 2025 availability update, Remote Pharmacy highlights the expanded access to non-branded GLP-1-based weight management options, including semaglutide and tirzepatide compounds

Further increases to 7.5mg, 10mg, 12.5mg, and 15mg occur at four-week intervals

In TRIUMPH-3, up to 13.5 percent of participants using retatrutide stopped early, compared with 4.8 percent taking a placebo